SCM
Silverarc Capital Management Portfolio holdings
AUM
$691M
1-Year Est. Return
359.36%
This Fund
S&P 500
1 Year Est. Return
+359.36%
AUM
$691M
AUM Growth
+$202M
(+41%)
Holding
91
Top Buys
| 1 | +$33.1M | |
| 2 | +$17.6M | |
| 3 | +$14.8M | |
| 4 |
Fractyl Health
GUTS
|
+$13.5M |
| 5 |
Biogen
BIIB
|
+$10.9M |
Top Sells
| 1 | +$39M | |
| 2 | +$33.9M | |
| 3 | +$20.5M | |
| 4 |
ETNB
89bio
ETNB
|
+$20M |
| 5 |
Soleno Therapeutics
SLNO
|
+$17.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ETNB
76
DELISTED
89bio
ETNB
| – | – |
-2,037,087
|
|
||
77
Structure Therapeutics
GPCR
$4.45B
| – | – |
-175,636
|
|
||
78
Hims & Hers Health
HIMS
$3.31B
| – | – |
0
|
|
||
|
MRUS
79
DELISTED
Merus
MRUS
| – | – |
-741,972
|
|
||
80
Neurocrine Biosciences
NBIX
$13.3B
| – | – |
-162,969
|
|
||
81
Pfizer
PFE
$157B
| – | – |
-344,338
|
|
||
82
Ultragenyx Pharmaceutical
RARE
$2.26B
| – | – |
0
|
|
||
83
Sagimet Biosciences
SGMT
$186M
| – | – |
-37,539
|
|
||
|
84
Soleno Therapeutics
SLNO
$2.1B
| – | – |
-204,591
|
|
||
|
TRML
85
DELISTED
Tourmaline Bio
TRML
| – | – |
-109,257
|
|
||
86
United Therapeutics
UTHR
$21.7B
| – | – |
0
|
|
||
|
VRNA
87
DELISTED
Verona Pharma
VRNA
| – | – |
-358,297
|
|
||
88
State Street SPDR NYSE Technology ETF
XNTK
$1.52B
| – | – |
0
|
|
||
|
ATYR
89
aTyr Pharma
ATYR
$94M
| – | – |
0
|
|
||
|
ORKA
90
Oruka Therapeutics
ORKA
$1.67B
| – | – |
-165,389
|
|
||
|
MTSR
91
DELISTED
Metsera Inc
MTSR
| – | – |
-207,581
|
|